Peter P. Pfreundschuh's most recent trade in Y-Mabs Therapeutics Inc was a trade of 63,500 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Y-Mabs Therapeutics Inc | Peter P. Pfreundschuh | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 63,500 | 63,500 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Peter P. Pfreundschuh | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 31,800 | 77,800 (0%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | Peter P. Pfreundschuh | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 170,000 | 170,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Peter P. Pfreundschuh | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 46,000 | 46,000 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Peter Pfreundschuh P. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.46 per share. | 21 Feb 2024 | 3,764 | 175,669 (0%) | 0% | 7.5 | 28,079 | Common Stock |
| Voyager Therapeutics Inc | P. Peter Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Pfreundschuh P. Peter | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 30,000 | 179,433 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 76,000 | 76,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 38,000 | 163,000 (0%) | 0% | 0 | Common Stock | |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.53 per share. | 18 Feb 2022 | 1,542 | 8,927 (0%) | 0% | 3.5 | 5,442 | Common Stock |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.88 per share. | 18 Feb 2022 | 1,404 | 10,469 (0%) | 0% | 3.9 | 5,443 | Common Stock |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 150,000 | 150,000 | - | - | Restricted Stock Unit | |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.20 per share. | 16 Feb 2022 | 1,296 | 11,873 (0%) | 0% | 4.2 | 5,443 | Common Stock |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.43 per share. | 16 Feb 2022 | 1,229 | 13,169 (0%) | 0% | 4.4 | 5,443 | Common Stock |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 15,000 | 15,745 (0%) | 0% | - | Common Stock | |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 15,000 | 15,000 | - | - | Restricted Stock Unit | |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.33 per share. | 14 Feb 2022 | 1,347 | 14,398 (0%) | 0% | 4.3 | 5,834 | Common Stock |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2021 | 30,000 | 30,000 | - | - | Restricted Stock Unit | |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option | |
| Frequency Therapeutics Inc | Peter P. Pfreundschuh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 230,000 | 230,000 | - | - | Stock Option | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 4,917 | 12,805 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,084 | 2,082 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.72 per share. | 15 Oct 2020 | 1,017 | 10,405 (0%) | 0% | 21.7 | 22,089 | Ordinary Shares |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.80 per share. | 15 Oct 2020 | 976 | 11,829 (0%) | 0% | 21.8 | 21,276 | Ordinary Shares |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 833 | 1,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.82 per share. | 15 Oct 2020 | 407 | 11,422 (0%) | 0% | 21.8 | 8,882 | Ordinary Shares |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 1,042 | 4,166 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 1,042 | 8,397 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.82 per share. | 01 Sep 2020 | 509 | 7,888 (0%) | 0% | 22.8 | 11,615 | Ordinary Shares |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2020 | 417 | 2,500 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2020 | 417 | 7,496 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Peter P. Pfreundschuh | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.51 per share. | 26 Jul 2020 | 141 | 7,355 (0%) | 0% | 23.5 | 3,315 | Ordinary Shares |